450 Brookline Avenue, Mayer 413
Boston, MA 02215
United States of America
Honors and awards
Dr. Lane’s research focuses on the biology of high-risk hematologic malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN), to identify novel therapeutic targets and to understand treatment resistance. He has also identified new cancer genes including tumor suppressors that escape X inactivation (EXITS genes) as mediators of sex bias in tumor genomes.
He is an associate professor of medicine at Harvard Medical School, a physician in the Leukemia Program, and a lab investigator in the Division of Hematologic Neoplasia in the Department of Medical Oncology at the Dana-Farber Cancer Institute. He is director of the BPDCN Center at Dana-Farber. He is also an associate member of the Broad Institute of Harvard and MIT.
Dr. Lane received a bachelor’s degree in biomedical engineering from Vanderbilt University, and an MD and PhD from Washington University. He completed a residency in internal medicine at Brigham and Women’s Hospital and fellowships in hematology and medical oncology at the Dana-Farber Cancer Institute.
Harvard Medical School, Dana-Farber Cancer Institute (Primary)
William C. Hahn, MD, PhD is the representative at this institution.